NRAS and hepatocellular carcinoma: This promoter switching may be important in HCC as altering the methylation status of P4 to reduce IGF2 expression enhances survival in a Hep3B liver cancer model [16] and reducing IGF2 levels by siRNA reduces c‐Myc and N‐Ras signaling in HCC.[17]